BC3402 not checked
Biocity Biopharmaceutics Co., Ltd.
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
3 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Subjects will receive BC3402 as a single agent via intravenous infusion once every 3-weeks (Q3W),the dose of BC3402 was calculated according to the dose group and body weight of the subjects.”In the company’s words, NCT05690425 on ClinicalTrials.gov
- Tested for
- Hepatocellular Carcinoma, Hematologic Malignancy, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
- Main trialPhase 1/2
- “Phase Ib: Dose exploration: To assess the safety, tolerability, and determine the recommended Phase 2 dose (RP2D) of BC3402 in combination with durvalumab in subjects with advanced hepatocellular carcinoma (HCC) Phase II: Dose Expansion: To assess the antitumor activity of BC3402 in combination with durvalumab in subjects with advanced HCC.”In the company’s words, NCT06111326 on ClinicalTrials.gov
- Other names
- not have
Other drugs for Hepatocellular Carcinoma
- CadonilimabAkeso · Phase 3
- DurvalumabAstraZeneca · Phase 3
- TremelimumabAstraZeneca · Phase 3
- BudigalimabAbbVie · Phase 2/3
- LivmoniplimabAbbVie · Phase 2/3
- BGB-B2033BeOne Medicines (BeiGene) · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Unknown | Aug 2024 | BC3402 in Combination With Durvalumab in Patients With Advanced Hepatocellular Carcinoma | |
| Phase 1Unknown | 15 Mar 2024 | A Phase I Study of BC3402 as a Single Agent in Patients With MDS and CMML | |
| Phase 1Unknown | Mar 2025 | Study of BC3402 in Combination With Azacitidine in Patients With MDS and CMML |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026